This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| H3 | |
|---|---|
| Name | H3 |
| Caption | Histone H3 core particle |
| Organisms | Eukaryota |
H3 is a core histone protein that forms part of the nucleosome core particle in eukaryotic chromatin, playing a central role in DNA packaging and regulation of gene expression. It participates in chromatin dynamics through post-translational modifications that influence processes such as transcription, replication, and DNA repair. H3 variants and their modification patterns are conserved across diverse taxa and are studied in relation to development, disease, and epigenetic inheritance.
The nomenclature for H3 includes canonical isoforms and replacement variants recognized across model organisms and institutions: canonical human forms are often labeled by gene names such as HIST1H3A and HIST2H3A in databases curated by the Human Genome Project consortia and cataloged by resources like UniProt and Ensembl. Replacement variants such as H3.3 map to genes like H3F3A and H3F3B, which were characterized in studies by researchers affiliated with Cold Spring Harbor Laboratory, Max Planck Society, and the Wellcome Trust. Specialized variants including CENP-A (centromere-specific H3) relate to centromere function studied by groups at European Molecular Biology Laboratory and institutions participating in the Human Cell Atlas. Evolutionary classification draws comparison to histone homologs discovered in organisms from Saccharomyces cerevisiae to Drosophila melanogaster and Arabidopsis thaliana, with phylogenetic analyses published by teams at Broad Institute and European Bioinformatics Institute.
H3 contributes two alpha-helices to the histone fold that assembles with H4, H2A, and H2B into the histone octamer described in structural studies from Rosalind Franklin-era diffraction improvements and later cryo-electron microscopy at European Synchrotron Radiation Facility and National Institutes of Health-funded centers. High-resolution structures reported by groups at Harvard Medical School and Stanford University reveal DNA wrapping ~1.65 turns around the octamer and specific residues in H3 that contact nucleosomal DNA. Biochemical properties such as basic charge, lysine-rich N-terminal tails, and conserved residues have been characterized in protocols developed at Cold Spring Harbor Laboratory and employed by labs at Max Planck Institute for Molecular Genetics. Mutational analyses linked to projects at Wellcome Sanger Institute and Howard Hughes Medical Institute detail effects on nucleosome stability and chromatin fiber folding observed in assays at Argonne National Laboratory.
H3 modifications and variant incorporation regulate transcriptional programs explored in work from National Cancer Institute, European Molecular Biology Organization, and consortia including the ENCODE Project. Specific post-translational marks—e.g., methylation at lysine 4 or lysine 36 and acetylation at lysine 9 or lysine 14—are associated with active or repressive chromatin states in studies by teams at Massachusetts Institute of Technology and Yale University. Deposition pathways involving chaperones such as HIRA and DAXX have been elucidated by investigators at University of Cambridge and University of California, Berkeley, while centromeric H3 variant function is a focus for researchers at Johns Hopkins University and MIT McGovern Institute. Roles in DNA damage response, replication timing, and epigenetic memory were detailed in collaborations involving European Research Council grants and laboratories at Columbia University.
Somatic mutations in H3 genes, including lysine-to-methionine substitutions, are implicated in pediatric gliomas and were first reported by clinical teams at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute; those findings prompted diagnostic panels developed at Mayo Clinic and Memorial Sloan Kettering Cancer Center. Altered H3 modification landscapes are biomarkers studied in translational programs at National Cancer Institute and pharmaceutical groups at Novartis and Roche for prognostic relevance in malignancies. Assays for H3 variant expression and modification—implemented in pathology labs at Johns Hopkins Hospital and Cleveland Clinic—use immunohistochemistry and mass spectrometry platforms standardized by consortia including Clinical Laboratory Improvement Amendments-related networks.
Experimental approaches to study H3 include chromatin immunoprecipitation (ChIP-seq) pipelines refined by the ENCODE Project and executed in sequencing centers at Broad Institute and Wellcome Sanger Institute, native mass spectrometry protocols from Argonne National Laboratory, and single-molecule imaging at National Institute of Standards and Technology. Genetic perturbation strategies—CRISPR screens and knock-ins—are widely used in labs at Broad Institute, Stanford University, and MIT to assess variant function. Structural studies utilize cryo-EM facilities at EMBL and synchrotrons at Diamond Light Source; epigenomic profiling integrates methods from European Bioinformatics Institute and computational pipelines from National Center for Biotechnology Information.
Targeting enzymes that write, erase, or read H3 marks—methyltransferases, demethylases, acetyltransferases, bromodomain proteins—has driven drug discovery programs at GlaxoSmithKline, Pfizer, and academic drug centers at University of Oxford and UCSF with clinical candidates entering trials overseen by Food and Drug Administration. Epigenetic editing approaches using programmable DNA-binding platforms have been developed in collaborations between Broad Institute and Harvard Medical School with potential for correcting dysregulated H3 modification states in disease models studied at Massachusetts General Hospital and Sloan Kettering Institute. Biomarker-driven precision medicine initiatives incorporating H3 mutation status are pursued by consortia including NCI MATCH and center networks like European Society for Medical Oncology.
Category:Histones